SEARCH BUTTON
HOME > IQS TECH TRANSFER > TEAM > Benjamí Oller-Salvia, PhD

Benjamí Oller-Salvia, PhD

Associate Professor - Junior Leader F. La Caixa - ERC Grantee
+34932672000

RESEARCH LINES

  • Development of peptides for biomedical applications.
  • Generation of selectively modified therapeutic proteins by genetic code expansion and bioorthogonal chemistry.
  • Design of vectorised drug delivery systems, mainly targeting the brain.
  • Development of stimuli-responsive proteins and nanomaterials.

 

COORDINATOR:

ChemSynBio

CHEMICAL & SYNTHETIC BIOLOGY FOR BIOTHERAPIES

School of Engineering

Chemical & Synthetic Biology for Biotherapies

This group combines chemistry and synthetic biology to develop precision bio-nano-therapeutics based on smart proteins and to generate molecular systems that enable transport of therapeutics to the brain.

MEMBER OF:

GEMAT

Grup d'Enginyeria de Materials

School of Engineering

Materials Engineering

Its activities focus on three main areas: the development of new functional materials, surface engineering and biomaterials.

LATEST PROJECTS

OBGate (Creating an orthogonal gate to the brain)

Change of paradigm in the the field of brain delivery: opening a new Orthogonal Brain Gate where targeted drugs will be able to cross the blood brain barrier for the treatment of brain diseases
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)

APTIBody (Nanoterapias de Glioma)

Estrategia para generar anticuerpos activables y su aplicación para dirigir nanoterapias génicas a células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)

PRO-ANTIBODY (Activación selectiva de Anticuerpos contra el Glioblastoma)

Desarrollo de anticuerpos activables para la administración de terapias génicas en las células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)
1 2
Search more projects

LINKED NEWS

Research

New Peptide and Protein Characterization and Purification Instruments

18/05/2022
IQS has acquired three chromatography instruments for peptide and protein characterization and purification, with funding from the Fundación “la Caixa” Junior Leader Fellowships programme.
READ FULL NEW
Research

Activatable antibodies in targeted therapies

18/02/2022
Dr Oller from IQS has recently received a grant from the Semilla programme with the Spanish Cancer Society (AECC) to work on new types of activatable antibodies against a specific marker of resistant cancer cells.
READ FULL NEW
Research

Activatable Antibodies to Increase Selectivity for Brain Tumour Therapies

19/10/2021
In the Materials Engineering Group (GEMAT) at the IQS School of Engineering, the team led by Dr Benjami Oller Salvia is working to take on two of the great challenges with GBM therapies.
READ FULL NEW
Search all news